Health committee  I can respond to that, Madam Chair. Our framework is as it is. We do look at risk. We look at risks to intended patients, the ones that the drug is supposed to be used by, and we ensure that it's labelled properly. We have a parallel set of regulatory frameworks that looks at th

Health committee  Madam Chair, my response would be this. In Canada, under the Food and Drugs Act and its regulations, a drug will be issued a market authorization if, after a risk-based decision-making process, Health Canada determines that the drug demonstrates safety, efficacy, and quality unde

Health committee  I would just add that at more of an operational level, now when we approve an new opioid and it reaches the NOC stage, when it gets to notice of compliance, we're making sure that we're sending out information to a number of affected parties, provincial-level bodies as well as ph

Health committee  I can speak from the licensing perspective around labelling. Certainly, when a drug comes in for approval and it's clear that it has addictive or abuse potential, we spend a fair bit of time looking at the labelling and ensuring that when the product is authorized on the market